Breast Cancer Screening Tests Market

Breast Cancer Screening Tests Market Snapshot

The global breast cancer screening tests market was valued at USD 1.9 Billion in 2022 and is expected to reach USD 4.4 Billion by 2033. The imaging tests segment with around 54.3% value share, has topped the global market within the product category in 2022 and is expected to grow at a CAGR of close to 7.8% over the forecast period (2023 to 2033)

Market Outlook:

Data Points	Market Insights
Market Value 2022	USD 1.9 Billion
Market Value 2023	USD 2.1 Billion
Market Value 2033	USD 4.4 Billion
CAGR 2023 to 2033	7.8%
Market Share of Top 5 Countries	54.5%
Key Market Players	AstraZeneca; Novartis; Sanofi; Pfizer; Bayer AG; GlaxoSmithKline plc; and Siemens Healthineers; Hologic Inc.

Diagnostic tests are critical in giving accurate care to patients. More precise breast imaging technologies have been developed over the last decades, which has helped to minimise the disease burden of breast cancer.

Since breast cancer is one of the most common cancers in women, the development of various breast cancer awareness programmes has been critical, and many agencies, including the FDA, have launched breast cancer awareness programmes such as the Pink Ribbon Sunday Mammography Awareness Program.

Sales Analysis of Breast Cancer Screening Tests Market from 2017 to 2022 Vs Market Outlook for 2023 to 2033

The global market for breast cancer screening tests was around 1.0% of the overall USD 191.0 Billion of the global cancer diagnostics market in 2022.

Growing demand for technologically sophisticated testing kits and instruments that may improve accuracy, speed, and cost-effectiveness for diagnosis is expected to be the most important growth factor over the projection period.

Rising reimbursement and insurance coverage are likely to further boost testing adoption. Government bodies across various countries have approved certain tests for nationwide reimbursement. This has led to an increase in number of tests being performed either at point-of-care testing site or at the convenience of home.

• For instance, In the United States, along with many third-party payer benefit plans, Medicare, and Medicaid, also cover the cost associated with genetic testing. Most insurance plans cover genetic tests for condition like Breast Cancer Type 1 (BRCA1) and Type 2 (BRCA2), for people with a family history of cancer.

Patient advocacy organisations and organisations dedicated to breast cancer awareness and assistance are critical in boosting demand for screening tests. These organisations educate and empower women, advocate for the necessity of screening, and work to improve access to screening services.

Breast cancer screening test reimbursement policies and insurance coverage are thus, critical in driving market growth. Beneficial reimbursement policies make screening tests more accessible and inexpensive to patients, resulting in greater utilisation and demand.

Women are becoming more aware of the importance of breast health and regular screenings. Patients are increasingly taking an active role in their own health management, including seeking screening tests. These factors produces an opportune environment for the expansion of the breast cancer screening tests market.

Owed to the above factors, the global market is projected to grow at CAGR of 7.8% in forecasted period.

What are the Key Opportunities for the Breast Cancer Screening Test Kits Manufacturers?

Breast cancer is one of the most common cancers among women around the world.

• According to data by National Center for Health Statistics-2023, there will be an expected 297,790 new instances of advanced breast cancer diagnosed in women in 2023.

Early diagnosis using screening tests is critical for improving treatment outcomes and lowering mortality rates. As a result of the rising incidence and prevalence of breast cancer, the demand for screening tests is increasing.

Worldwide initiatives and awareness campaigns to encourage breast cancer screening have been established by governments and healthcare organizations.

• For instance, in February 2023, a new Global Breast Cancer Initiative Framework was published by the World Health Organization (WHO). The framework serves as a road map for achieving the goal of saving lives of 2.5 million people from breast cancer by the end of 2040.

These programs seek to inform the public about the value of early detection and motivate women to have routine screenings. Increased screening rates are a result of government funding and awareness programs, which further fuel the market.

Genetic testing for breast cancer susceptibility, such as BRCA gene testing, has gained prominence. Advances in genetic testing technologies and increased understanding of the genetic factors contributing to breast cancer risk have expanded the scope of screening. Genetic testing drives the adoption of personalized screening approaches and fuels market growth.

What are the Factors Restraining Demand for Breast Cancer Screening Tests?

Breast cancer screening procedures, particularly mammography, can occasionally produce false-positive results, necessitating extra testing, biopsies, and concern for patients. Over diagnosis, or the detection and treatment of tumours that may or may not have caused harm, is also a source of worry. False positives and over diagnosis can increase healthcare expenses and endanger patients.

The most commonly used screening technique, mammography, may have limits in detecting breast cancer in individuals with dense breast tissue. Dense breasts have more fibrous and glandular tissue, making it difficult to detect minor abnormalities. Because of this limitation, women with dense breasts may have missed or delayed diagnoses, necessitating the adoption of additional screening procedures.

The cost of breast cancer screening tests, particularly more advanced imaging methods like breast MRI and molecular breast imaging, can be prohibitively expensive for certain people. Screening test costs and availability can vary depending on healthcare systems, insurance coverage, and individual financial circumstances. High costs may deter people from getting recommended screenings.

Country-wise Insights

Why is USA a Prominent Market for Breast Cancer Screening Test in North America Region?

The USA occupies 31.4% of market share in 2022 globally. The expansion of the breast cancer screening tests market in the United States is highly impacted by a variety of variables, including public awareness initiatives, government policies, and technological advancements.

The United States Preventive Services Task Force (USPSTF) announced new drafting guidelines for breast cancer screening in May 2023, which significantly reduced the age at which women should begin screening from 50 to 40 years old. The main advantage of screening is that it allows for earlier detection of breast cancer. Breast cancer is virtually 100 percent treatable when detected early. 

The USPSTF emphasised the importance of greater research regarding screening inequalities across different racial groups in the United States, as well as the benefits of breast ultrasonography and MRI for women with thick breasts.

The goal of these initiatives is to promote regular breast cancer screening, improve early detection rates, and ultimately reduce breast cancer mortality rates.

What Makes China a Highly Lucrative Market for Breast Cancer Screening Test?

China expenditure on breast cancer screening test in 2022 was USD 122.4 Million.

The growing middle-class population in China has largely contributed to the expansion of the breast cancer screening tests market. Breast cancer screening tests are anticipated to become more popular as more individuals obtain access to healthcare facilities.

More importantly, advances in medical technology and the availability of novel screening techniques have supported market expansion. Digital mammography, breast ultrasonography, and breast magnetic resonance imaging (MRI), for example, are becoming more popular in China for breast cancer screening and diagnosis.

What Makes the Germany a Large Market for Breast Cancer Screening Test?

In 2022, the Germany held a significant share in the global market and contributed around USD 132.3 Million. Breast cancer is a major public health concern worldwide, especially in Germany.

Breast cancer screening programmes are in existence in Germany, like in other industrialised nations, to diagnose breast cancer at an early stage. For example, in May 2023, ESMO Breast Cancer conference was held in Germany for breast cancer researchers and physicians with a focus on innovation and care. This campaign was primarily concerned with current advancements in innovative breast cancer diagnostics, biomarkers, and treatments.

These programs usually include mammography screening for women of specific ages.

Category-wise Insights

Which Diagnostics Test Type Is Predicted to Expand Rapidly Between 2023 and 2033?

By diagnostic test type, imaging tests held 54.3% market share in world in 2022.

Imaging tests are the most effective technique to detect breast cancer early, when it is easier to treat and before it has grown large enough to produce symptoms. Regular imaging tests, such as mammograms, can help to reduce the chance of dying from breast cancer. A mammography is currently the most extensively used tool for detecting breast cancer in most women of screening age. These considerations are increasing the use of imaging testing.

Which End User is Benefiting the Global Market?

The hospitals have a considerable presence in the breast cancer screening tests market, accounting for 42.3% value share in 2022, and exhibiting a high CAGR of 7.1% over the forecast period. The development of improved screening tests for cancer diagnosis and the rise in annual patient visits to hospitals around the world are both contributing factors to the rising usage of genetic testing.

Increasing government initiatives to equip hospitals with cutting-edge technology are some of the reasons that are fuelling the growth of this market.

Competitive Landscape

Collaborations and partnerships among healthcare providers, research institutions, and technology businesses can encourage innovation and hasten breast cancer screening test. Collaboration in research, development, and commercialization can lead to market expansion and the creation of new applications. Numerous large firms compete in the field of breast cancer screening test. Among the well-known players in this field are:

• March 2022, The Indian-based healthcare business Niramai Health Analytix now gets US FDA authorization for its first product, the SMILE-100 System, which offers a unique radiation-free, non-touch, accurate breast cancer screening option in India.
• In April 2023, Syantra Inc., based in Canada, has obtained CE mark clearance for their Syantra DX breast cancer test.

Similarly, recent developments related to the company’s manufacturing the breast cancer screening test kits have been tracked by the team at Future Market Insights, which are available in the full report.

Report Scope as Per Breast Cancer Screening Test Industry Analysis

Attribute	Details
Forecast Period	2023 to 2033
Historical Data Available for	2017 to 2022
Market Analysis	USD Million for Value
Key Regions Covered	North America; Latin America; Europe; South Asia; East Asia; Oceania; Middle East and Africa (MEA)
Key Countries Covered	USA, Canada, Brazil, Mexico, Argentina, Germany, Italy, France, UK, Spain, BENELUX, Russia, China, Japan, South Korea, India, Indonesia, Thailand, Philippines, Malaysia, Australia, New Zealand, GCC countries, Türkiye, Northern Africa and South Africa.
Key Market Segments Covered	Diagnostic Test, Type End, User and Region
Key Companies Profiled	AstraZeneca; Novartis; Sanofi; Pfizer; Bayer AG; GlaxoSmithKline plc; Siemens Healthineers; Hologic Inc.; General Electric Company; Koninklijke Philips NV; Fujifilm Holdings; A&G Pharmaceutical, Inc.; Biocrates Life Sciences AG; Metabolomic Technologies, Inc.; Myriad Genetics; OncoCyte Corporation; POC Medical Systems, Inc.; Hologic, Inc.; Provista Diagnostics, Inc.; BioTime, Inc.
Report Coverage	Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives
Pricing	Available upon Request

Key Market Segments Covered in the Breast Cancer Screening Test Industry Research

By Diagnostics Test Type:

• Blood Marker Tests
• Imaging Test
  • Mammography
  • MRI screening test
  • Molecular Breast Imaging Test
  • PET scan
  • Ultrasound
• Genetic Test
  • Fluorescence In Situ Hybridization
  • HER gene test
• Immunohistochemistry Test

By End User:

• Hospitals
• Diagnostic Centres
• Cancer Institutes
• Research Laboratories

By Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East and Africa

Frequently Asked Questions

How big is the Breast Cancer Screening Tests Market?

The market is valued at USD 2.1 billion in 2023.

Who are the Key Breast Cancer Screening Tests Market Players?

GE Healthcare, Siemens Healthineers, Fujifilm Holdings Corporation, and Hologic Inc. are key breast cancer screening test market players.

Which is the Key Segment by Product Type?

Mammography is the key segment by product type and is likely to remain preferred through 2033.

What is the Go-to-Market Strategy?

Players opt for product launches, partnerships, and mergers and acquisitions.

Which are the Key Asian Countries in the Breast Cancer Screening Tests Market?

China, India, and Japan dominate the Asian market.